IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

NCT01009840 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: IV busulfan
DRUG: bortezomib
PROCEDURE: Autologous Hematopoietic Stem Cell Transplant (HSCT)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.